Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Turkey / NCT07289009
Starting soon Not applicable

Adaptation and Implementation of the InterRAI-HC System Used in Home Health Care Services in Turkish

NCT07289009 · tracked via the Priya Life Science Turkey tracker
Sponsor
Hacettepe University
Phase
Not applicable
Started
2026-01-25
Last updated
2025-12-17

Condition(s) studied

Home Health Care

Investigational drug(s) / intervention(s)

Care supports

Care supports: The intervention of the study involves providing nursing care to the elderly individual and caregivers using care plans designed by the researcher, utilizing a validated scale. The adapted scale provides a comprehensive geriatric assessment. Emerging issues will be evaluated using NANDA diagnoses and NIC interventions/NOC outcomes. Individuals in the intervention group will be followed up for 6 months with these care plans. No interventions other than the services provided under ESH will be performed on individuals in the control group. The adapted questionnaire and specified scales will be administered simultaneously at the initial interview (0 months) and at 6 months for individuals in this group.

Study summary

This study was designed with a methodological approach. The first phase of the study consists of establishing the validity and reliability of the "International Resident Assessment Instrument-Home Care (InterRAI-HC)" application in Turkish. The second phase of the study involves comparing the standard forms used in Home Health Services units with the adapted InterRAI scale. The study population will consist of caregivers of individuals aged 65 and over who apply to the home health services unit of a healthcare institution in Kars province. The interRAI-HC questionnaire, SF-12 scale, and nursing care plans will be used to collect data. The aim of the study is to develop a comprehensive geriatric assessment tool for use in home health services.

Eligibility

Sex
ALL
Min age
65 Years
Max age
—
Healthy volunteers
Accepted
Inclusion criteria; * Being registered with ESYS (Home Health Care Management System), * Volunteering to participate in the study * Having a caregiver Exclusion criteria: • Not knowing Turkish Withdrawal criteria from the study: * Refusing two or more scheduled visits, * Withdrawing at the individual's own request, * Providing incomplete or incorrect responses.

Primary outcome measure(s)

  • SF-12 — 6 months
    The SF-36 Scale consists of 12 selected questions from the SF-36 Questionnaire. In 1992, the Rand Corporation developed and released the SF-36 Health Survey. Koçyiğit and colleagues established its validity and reliability in Turkish. The SF-12 consists of eight subscales. Scores ranging from 0 to 100 can be obtained from the scale. Higher scores indicate a higher quality of life.

Trial sites (1)

FacilityCityRegionStatus
Harakani State Hospital Kars Merkez

More Hacettepe University trials in Turkey

Body Composition and Psychosocial Factors in ICI-Treated Cancer Patients Recruiting
Effects of Rigid Taping in Acromioclavicular Joint Degeneration Recruiting
Investigation of the Validity, Reliability, and Responsiveness of BETY-BQ in Chronic Kidney Disease, on Dialysis, and Kidney Transplantation Recruiting
Clinical Evaluation of a Restorative Glass Ionomer and a Bulk-fill Composite Resin Active, not recruiting
Physical Functions and Lifestyle Behaviours in Post-COVID-19 Syndrome Based on Circadian Rhythms Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07289009 on ClinicalTrials.gov ↗ ← All trials in Turkey